D S Kaufman
Overview
Explore the profile of D S Kaufman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1316
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gori J, Tian X, Swanson D, Gunther R, Shultz L, McIvor R, et al.
Gene Ther
. 2009 Oct;
17(2):238-49.
PMID: 19829316
Human embryonic stem cells (hESCs) provide a novel source of hematopoietic and other cell populations suitable for gene therapy applications. Preclinical studies to evaluate engraftment of hESC-derived hematopoietic cells transplanted...
2.
Penkman K, Kaufman D, Maddy D, Collins M
Quat Geochronol
. 2009 Aug;
3(1-2):2-25.
PMID: 19684879
When mollusc shells are analysed conventionally for amino acid geochronology, the entire population of amino acids is included, both inter- and intra-crystalline. This study investigates the utility of removing the...
3.
Michaelson M, Regan M, Oh W, Kaufman D, Olivier K, Michaelson S, et al.
Ann Oncol
. 2009 May;
20(5):913-20.
PMID: 19403935
Background: This study explored the efficacy and tolerability of sunitinib, an inhibitor of tyrosine kinase receptors, in men with castration-resistant prostate cancer (CRPC). Methods: Men with no prior chemotherapy (group...
4.
Kaufman D
Ann Oncol
. 2006 Jun;
17 Suppl 5:v106-12.
PMID: 16807436
Seventy to eighty percent of patients with newly-diagnosed bladder cancer will present with superficial tumors (Ta, Tis or T(1)). There is, however, a continuum between superficial and muscle-invasive cancer, with...
5.
Tay M, Kaufman D, Regan M, Leibowitz S, George D, Febbo P, et al.
Ann Oncol
. 2004 May;
15(6):974-8.
PMID: 15151957
Background: Medical or surgical castration is effective in advanced prostate cancer but with profound side-effects, particularly on sexual function. Effective, less toxic therapies are needed. This study examined whether the...
6.
Michaelson M, Shipley W, Heney N, Zietman A, Kaufman D
Br J Cancer
. 2004 Feb;
90(3):578-81.
PMID: 14760367
Invasive transitional cell carcinoma (TCC) of the urinary bladder is traditionally treated with radical cystectomy. This approach results in great morbidity and lifestyle changes, and approximately half of the patients...
7.
Kaufman D
Yale J Health Policy Law Ethics
. 2003 Apr;
2(1):109, 177-87.
PMID: 12664943
No abstract available.
8.
Shipley W, Kaufman D, Zehr E, Heney N, Lane S, Thakral H, et al.
Urology
. 2002 Jul;
60(1):62-7; discussion 67-8.
PMID: 12100923
Objectives: To evaluate the outcomes of patients with muscle-invasive Stage T2-4a bladder carcinoma managed by transurethral surgery and concurrent chemoradiation. Methods: A total of 190 patients were treated on institutional...
9.
Kaufman D, Thomson J
J Anat
. 2002 May;
200(Pt 3):243-8.
PMID: 12033728
Human embryonic stem (ES) cells provide a novel opportunity to study early developmental events in a human system. We have used human ES cell lines, including clonally derived lines, to...
10.
Oh W, George D, Kaufman D, Moss K, Smith M, Richie J, et al.
Semin Oncol
. 2001 Oct;
28(4 Suppl 15):40-4.
PMID: 11685727
Effective treatment options for high-risk localized prostate cancer are limited. Patients at high risk for recurrence include those with biopsy Gleason scores of 8 to 10, prostate specific antigen (PSA)...